Aim Diff erent biodegradable-polymer drug eluting stents have not yet been systematically analysed. We sought to; 1) evaluate the risk of target lesion revascularisation (TLR) and defi nite stent thrombosis (DST) among diff erent groups of biodegradable-polymer (BioPol) DES, and 2) to compare them with permanent polymer (PermPol) DES. At 30 days, there was a higher risk of DST (p=0.04) and subsequently TLR (p=0.006) in the BioPol-BES compared to BioPol-SES, with no signifi cant diff erence in the other stent comparisons. At 1 year, there was higher risk of TLR in the BioPol-PES (p= 0.01), and the BioPol-SES (p=0.04) compared to BioPol-BES. One-year stent thrombosis was not statistically diff erent between the studied groups (overall p= 0.2). In another analysis comprising 7 randomised trials comparing BioPol-DES (3778 patients) and PermPol-DES (3291 patients), the risks of TLR and stent thrombosis at 1 year were not signifi cantly diff erent (p= 0.5 for both).
INTRODUCTION
Drug eluting stents (DES) represent a major breakthrough in the fi eld of percutaneous coronary interventions (PCI), since they have dramatically reduced the need for repeated revascularization procedures 1, 2 .
Along with the increasing number of patients receiving DES and the availability of long-term follow-up data, concern has arisen regarding the safety of these devices with the potential for increased infl ammatory response and stent thrombosis which could have life-threatening consequences [3] [4] [5] .
Polymers used for the delivery of antirestenotic agents have been accused for the development of late stent thrombosis. This is thought to be secondary to polymer-induced infl ammatory reaction, with delayed healing and re-endothelialization of the DES 6 . Given these issues more focus has been placed upon developing bio-degradable polymers, which degrade over time, and therefore possibly eliminate the problems of polymer-induced infl ammation.
In some cases, fi ndings from pre-clinical studies can be misinterpreted, especially in cases where the drug may be toxic. The polymer may be blamed for the infl ammation or excessive fi brin deposition and lack of endothelialization. Yet the diff erence in pharmacokinetics and anti-restenotic effi cacy of the diff erent drugs could also be held responsible for variation in clinical outcomes. Thus, a "polymer only" control is essential in distinguishing the culpability between polymer versus drug 7 . However, this is a control diffi cult to implement in clinical studies.
Various studies were conducted to test the clinical performance of a variety of biodegradable polymer-based stents eluting sirolimus (BioPol-SES), biolimus A9 (BioPol-BES) or paclitaxel (BioPol-PES).
The aims of the present meta-analysis were: 1) to compare the short term (1 month) and mid-term (1 year) performance of sirolimus, biolimus A9 and paclitaxel biodegradablepolymer DES and 2) to compare, where information was available, the 1-year performance of biodegradable-polymer DES (BioPol-DES) with permanent-polymer DES (PermPol-DES).
METHODS

Eligibility and search strategies
To be included in this meta-analysis, studies had to meet the following criteria: (a) Implantation of a drug eluting stent with biodegradable polymer; (b) available follow-up data for at least one of the clinical end-points at short term (30 days) and/or mid-term (up to one year).
Studies dedicated to specifi c lesion subsets including; left main stenting, bifurcation lesions, chronic total occlusions, long lesions, in-stent restenosis and venous grafts were excluded. No language restriction was applied. additional clinical trials from relevant websites (total of 325 citations) ( Figure 1 ). After reading the titles and abstracts, a total of 25 potentially relevant studies were initially identifi ed from which 22 were eligible for inclusion.
Data abstraction
Defi nitions and end-points
The clinical end-points of the study were the rates of target lesion revascularization (TLR) and defi nite stent thrombosis (DST) at 30 days and one year follow-up. Even in the few studies with follow-up more than one year only the data at one year were used.
TLR was defi ned as percutaneous or surgical revascularization of the target lesion. Defi nite stent thrombosis was defi ned, whenever available, according to the defi nition of the Academic Research Consortium 8 .
Statistical analysis
For the comparison of the 3 biodegradable-polymer stent types (BioPol-SES, BioPol-PES and BioPol-BES), 20 studies provided one patient series and 2 studies provided two patient series. Since there were only two studies with two series, we analyzed the 24 patient series as independent studies. For each patient series we extracted from the publications the number of events (TLR or DST within 30 days or one year) and the corresponding number of patients. For each stent type, type of event and follow-up period the exact 95% confi dence interval for a binomial proportion was calculated and depicted in a forest plot. If the observed proportion was zero, the one-sided 97.5% confi dence interval was given. To compare the incidences of the diff erent types of events between the diff erent stent types, we used random eff ects meta-analysis. More specifi cally, we used random intercept logistic regression with two dummy variables representing the three stent types, as described in Stijnen et al 9 .
This analysis assumes that the between studies variance was equal for the diff erent stent types. In the analysis, the random eff ects take into account the possibility that there may be many diff erences between the patient populations of the diff erent studies, infl uencing the risks of the considered endpoints. To adjust for multiple comparisons, we fi rst tested at α=0.05 the overall null hypothesis that all three stent types had equal incidence. If this test was signifi cant, the three pair-wise tests were done at α=0.05. For the incidence of TLR within 30 days, the estimate of the between studies variance was zero. In that case the analysis reduces to ordinary logistic regression and we used exact tests and confi dence intervals for the odds ratios.
Seven studies comprised trials comparing BioPol-DES with PermPol-DES. To make forest plots, we calculated exact 95% confi dence intervals for the odds ratio except for studies in which less than 2 events in total were observed. We used random eff ects meta-analysis to estimate and test the overall odds ratio across studies. Due to the scarcity of data at 30 days among the included studies, we decided to assess the events at 1 year only. Because of the small numbers of events in some of the studies, the hypergeometric-normal model as described in Stijnen et al was used 9 .
All statistical analyses were performed using SAS statistical package version 9.1.3. The procedure NLMIXED was used for the random-eff ect meta-analysis. 
Study Quality assessment
This meta-analysis was especially designed to extract data from various types of available studies: observational studies presenting data about BioPol-DES; randomized clinical trials (RCTs) in which diff erent BioPol-DES are compared among each other, and RCTs in which BioPol-DES is compared with PermPol-DES. Only for the latter category, it was of interest to perform an RCT study quality assessment. We have used the Delphi list for the quality assessment of RCTs as described by Verhagen et al 10 
RESULTS
Trials and study characteristics
A total of 22 studies 11-33 with a total of 8264 patients were included in this meta-analysis ( Among the included studies there were 10 randomized clinical trials (RCT) 13-16, 19, 22, 23, 25, 29, 32, 33 , two studies were randomizing BioPol-SES versus BioPol-PES 23, 32 , two studies; one randomizing BioPol-SES versus permanent polymer sirolimus eluting stent (PermPol-SES) 13, 25 , and another randomizing BP-SES versus permanent polymer sirolimus (PermPol-SES) plus everolimus eluting stents (PermPol-EES) 14 , one study randomizing BioPol-PES versus permanent polymer paclitaxel eluting stent (PermPol-PES) 22 , two studies randomizing BioPol-BES versus
PermPol-SES 29, 33 , two studies randomizing BioPol-BES versus PermPol-PES 15, 16 , and fi nally one study randomizing BioPol-BES versus bare metal stent 19 . Clinical end-points at 30 days follow-up (Table 2) TLR Among the studied population the incidence of TLR at 30 days was 0.4% in the BioPol-SES, 0.7% in the BioPol-PES and 1.4% in the BioPol-BES. These incidences were statistically signifi cantly diff erent (overall p-value=0.01); the three pair-wise comparisons were; OR= 3.4, 95%CI= 1.3-9.6, p=0.006 for BioPol-BES vs. BioPol-SES, OR= 1.7, 95%CI= 0.6-5.1, p= 0.3 for BioPol-PES vs. BioPol-SES and OR= 2.0, 95%CI= 0.9-4.7, p= 0.08 for BioPol-BES vs. BioPol-PES.
DST
The incidence of DST at 30 days was 0.2% in the BioPol-SES, 0.3% in the BioPol-PES and 0.9 % in the BioPol-BES. The overall test on equality of these incidences showed a trend towards statistical signifi cance (p-value=0.06); the three pair-wise comparisons were; OR= 3.9, 95%CI= Clinical end-points at one year follow-up (Table 2) TLR Over a follow-up period up to 12 months, the incidence of TLR among the studied population was 4.9% in the BioPol-SES, 6.1% in the BioPol-PES and 2.3% in the BioPol-BES. These incidences varied signifi cantly among the diff erent stents (overall p-value=0.03). There was almost 3 times higher risk of TLR in the BioPol-PES compared to the BioPol-BES (OR=2.8, 95%CI= 1.3-6.0, p= 0.01), and twice higher risk of TLR in the BioPol-SES compared to BioPol-BES (OR=2.2, 95%CI= 0.2-1.0, p=0.04), and no signifi cant diff erence in the risk ratio of BioPol-SES vs. BioPol-PES (OR= 1.3, 95%CI= 0.6-2.6, p= 0.5).
The incidence of DST at one year follow-up was 0.3% in BioPol-SES, 1% in the BioPol-PES and 0.8% in the BioPol-BES. The pooled odds-ratio was not signifi cant among the diff erent stent
Clinical end-points at one year in randomized clinical trials of BioPol-DES vs. PermPol-DES (Table 3) In another analysis, in which clinical end-points were assessed in studies comparing BioPol-DES with PermPol-DES in a randomized manner (seven randomized controlled studies) 13-16, 22, 25, 29, 33 , it was observed that risk of developing TLR at 1 year follow-up was not signifi cantly diff erent in PermPol-DES compared to BioPol-DES (OR=0.8, 95% CI=0.5-1.4, p= 0.5) (fi gure 2). table for comparative purposes (see later table 4) Similarly, the one year risk of DST was not signifi cantly diff erent in PermPol-DES compared to BioPol-DES (OR=0.7, 95% CI= -0.2-2.4, p=0.5) (fi gure 3).
Randomized clinical trials quality assessment
Each of the RCTs comparing BioPol-DES with PermPol-DES had fi ve or more questions answered with 'yes' when assessed with the Delphi list. Therefore, all seven RCTs were considered to have a low risk of introducing bias in the assessment of TLR or DST in BioPol-DES vs. PermPol-DES.
DISCUSSION
Three types of biodegradable polymer based DES were analyzed in our study; sirolimus, paclitaxel and biolimus A9.
Rapamycin (sirolimus), is a macrolide with cytostatic properties that blocks progression from G1 to S in the cell cycle and inhibits thus the vascular smooth muscle cell migration and proliferation 34 .
Biolimus A9 is an analogue of rapamycin that binds to FK binding protein 12 and subsequently to the mammalian target of rapamycin. The formed complex inhibits smooth muscle cells proliferation by blocking the cell cycle progression between the G1 and S phase. The main diff erence between biolimus A9 and rapamycin is replacement of hydrogen by alkoxy-alkyl group at 40-O position, increasing its lipophilicity which is expected to optimize the drug distribution 16 . Two similar types of biolimus A9 eluting stents were tested in previous studies,
The BioMatrix ® (Biosensors International-Singapore) and The NOBORI ® (TERUMO Europe NV, Leuven, Belgium).
Paclitaxel inhibits vascular smooth muscle cell migration and proliferation mainly as a result of binding to and stabilizing cellular microtubules 34, 35 .
All stents are coated with a biodegradable poly-lactic acid (PLA) or poly-lactic-co-glycolic acid (PLGA) polymer 7 . In principle, after drug delivery and subsequent complete polymer degradation, only the biologically inert bare-metal platform remains.
To our knowledge this is the fi rst meta-analysis that compares the performance of diff erent DES with biodegradable polymers in a large cohort of patients with similar inclusion criteria, aiming to judge the individual drug performance without the infl uence of permanent polymer. The key fi ndings were that: a) the risk of TLR and DST were highest in the BioPol-BES group within short term follow-up (30 days); b) The risk of TLR at one year follow-up was three times higher in the BioPol-PES and twice higher in the BioPol-SES when compared to the BioPol-BES; c) There was no signifi cant diff erence in the one year risk of DST between the studied groups, however we could still observe a higher incidence of stent thrombosis in BioPol-PES compared to BioPol-SES (1% vs. 0.3%).
This meta-analysis is based on comparisons between studies. A consequence is that the results are more amenable to risk of bias than most meta-analyses, which are based on comparisons of meta-analyzed data randomized within studies. Thus our analysis yields valid results only under the assumption that, on the average, throughout these diff erent studies the patient populations are not systematically diff erent, though they are treated with diff erent types of biodegradable-polymer DES. In our view this assumption is likely to be fulfi lled since the inclusion and exclusion criteria were very comparable and were not diff erent between the groups of studies with diff erent types of stent.
In an additional analysis performed in randomized trials only, we found that the 1-year risks of TLR and DST were not signifi cantly diff erent between BioPol-DES and PermPol-DES.
Long term follow up results (> 2years)
are not yet fully available for the majority of biodegradable polymer DES and therefore we did not perform a long-term analysis.
Early stent thrombosis and target lesion revascularization (TLR)
One of the interesting fi ndings in this study was the signifi cantly higher incidence of early stent thrombosis (EST), within 30 days, in the BioPol-BES group, and the subsequent higher incidence of 30 days-TLR compared to BioPol-SES and BioPol-PES.
These results should be interpreted cautiously, especially in the considerations that polymeror drug-related stent thrombosis tends to present more likely as a mid-or late-term event,
and that most of the early thrombotic events which have occurred in the BioPol-BES group were encountered in the LEADERS trial 33 , which involved a diversity of complex lesions.
However, although ISAR TEST-IV trial 14 which tested BioPol-SES, had similar inclusion criteria and diverse complex lesions, yet resulted in less early thrombotic events. Moreover, when comparing the LEADERS 33 and NOBORI-2 18 clinical trials, the 2 leading "all comers" biolimus A9 trials, we could observe that the incidence of EST was obviously diff erent between both trials (1.6% vs. 0.1% respectively, Table 2 ).
It is still too early to adopt the hypothesis that a more intense antiplatelet regimen should be adopted in patients receiving BioPol-BES. Probably a more dedicated pharmacokinetic study, that addresses the issue of biolimus A9 tissue distribution and polymer degradation rates in diff erent settings as acute coronary syndromes and complex coronary lesions, would shed further light on this issue.
Target lesion revascularization (TLR) at mid-term follow-up (1 year)
From this study it was concluded that the incidence of TLR was signifi cantly lower in the BioPol-BES compared to both BioPol-SES and BioPol-PES. This goes along with the results of the NOBORI series of clinical trials 15, 16, 26, 29 . A sub-analysis of the LEADERS trial compared outcomes at 1 and 2 years 36 in BioPol-BES vs. PermPol-SES patients, stratifi ed according to Syntax score 37 tertiles. Authors showed that BES off ered signifi cant clinical benefi t over SES among patients with high Syntax scores, among which was signifi cantly less TLR at 1 year, with a strong trend at 2 years follow-up. Recently, the 3 years follow-up of the LEADERS trial has been announced, showing the sustained benefi t of BES over SES in patients with high
Syntax score and among patients with STEMI 38 . In view of these long-term results, it would be advisable to use BioPol-BES among patients with high-risk lesions.
Biolimus A9 possesses enhanced anti-infl ammatory and antiproliferative activity with an improved pharmacokinetic profi le. Unlike currently approved drug eluting stents utilizing drugs originally developed for other indications, biolimus A9 has specifi cally been developed for local delivery to coronary arteries 39 . Biolimus A9 is a novel rapamycin derivative that, like sirolimus, inhibits smooth muscle cell proliferation via binding to the FK-binding protein and subsequent inhibition of the mammalian target of rapamycin (mTOR) [40] [41] [42] .
The newly developed biolimus A9 eluting stents; Nobori ® and BioMatrix ® share several unique features. The most important are biodegradable polymer carrier (poly lactic acid), and coating only on the abluminal stent surface. The later feature allows direct release of biolimus A9
into the vessel wall and, enhanced by its high lipophilicity (~10-fold higher than sirolimus), fast uptake by the surrounding tissue 15, 16, 33, 43 .
It has been previously reported that sirolimus and paclitaxel drug eluting stents were associated with paradoxical coronary vasoconstriction up to 12 months after implantation [44] [45] [46] [47] . This observation may be attributable to delayed endothelialization caused by the drug and/or endothelial dysfunction caused by polymer-induced infl ammation or hypersensitivity reac-tion. On the contrary, in a recent study, it has been shown that biolimus A9 eluting stents are associated with better preserved endothelial function in coronary arteries compared to the fi rst generation DES, which could be partly explained by the better drug release kinetics 48 .
Animal studies showed that after BES implantation, the tissue concentration of the drug in segments 5 mm proximal and distal to the stent edges is almost non-measurable 43 . In addition, SES and BES have diff erent drug release kinetics: total drug content is released from the SES within 60 days with more than 60% released shortly after stent implantation 49 , versus a small initial burst and sustained simultaneous drug release and polymer degradation taking place over 6-9 months in the BES 43 , exposing the surrounding tissue at any given time to a lower amount of drug.
Defi nite stent thrombosis (DST) at mid-term follow-up (1 year)
Because durable polymers have been held responsible for some of the thrombotic events that are assumed to occur as a result of polymer-mediated infl ammatory reaction and delayed endothelialization, it was expected that degradation of the polymer will improve arterial healing and thus negate this adverse outcome. This leaves us with the assumption that a higher incidence of thrombotic events, if any, would be a "drug only" eff ect.
In this meta-analysis, the risk of DST was not signifi cantly diff erent between the diff erent BioPol-DES at one year follow-up; however we could still observe that the incidence of stent thrombosis was numerically 3 times lower in SES vs. PES (0.3% vs.1% respectively). Previous data, comparing fi rst generation DES, have shown that there is higher risk of ST in PES compared to SES 3, 50, 51 .
Biodegradable-polymer Biolimus A9 stents (BioMatrix® vs. NOBORI®)
Despite using the same biodegradable polymer (poly-lactic acid) coated on the abluminal stent surface, recent pharmacokinetic studies of the two main biolimus A9 stents; Biomatrix ®52 and NOBORI ®43 , have shown that there is an obvious diff erence between the pharmacokinetics of the the two main biolimus A9 stents, which may be an explanation for the more favourable clinical outcomes encountered with the latter (Table 4 ).
The NOBORI ® stent design and coating process diff er from that of the BioMatrix ® stent. The maximum Biolimus A9 concentrations in blood with a median of 18 pg/mL (range<LLOQ to 32 pg/mL) and the AUC 0- (median 2.9 ng/mL·h, range <LLOQ to 33.1 ng/mL·h) were lower than those after BioMatrix ® implantation, suggesting that stent design and coating process have an impact on Biolimus A9 release kinetics.
In addition to drug distribution and elimination, biolimus A9 pharmacokinetics are significantly aff ected by the polymer degradation rate which in turn is infl uenced by the state of the vessel. In a vessel with infl ammation, the pH is expected to be low which will accelerate the degradation of the polymer material and the subsequent drug release into the vessel wall 7
Clinical outcomes in randomized clinical trials of BioPol-DES vs. PermPol-DES
In the sub-analysis confi ned to randomised clinical trials comparing BioPol-DES and PermPol-DES, it was found that the risks of TLR or late DST at 1 year were not signifi cantly diff erent between both groups.
Unexpectedly, it was found that the presence of biodegradable polymeric coating did not infl uence the risk of stent thrombosis in DES at 1 year follow-up. A lot of awareness has been raised lately about the biocompatibility of permanent polymer implants and their potential role in contributing to stent thrombosis. Many animal studies have shown that a hypersensi- t max , time to maximum concentration; t last , time to last quantifi able biolimus A9 concentration (<10 pg/ ml); LLOQ, lower limit of quantitation (<10 pg/ml); C max , maximum concentration; C last , last quantifi able concentration; AUC 0-τ , area-under-the-time-concentration curve over the observation period; TLR, target lesion revascularization; DST, defi nite stent thrombosis. Values are expressed as mean ± SD and median (minimum -maximum) or as percentages (%). * Using automatic micropipette coating (AMPC) process. † Percentages between parentheses show the incidence of DST after including NOBORI-2 results; taking in consideration that they include defi nite & probable stent thrombosis.
tivity reaction may occur as a result of polymer induced infl ammation 7, 53 . Given these issues more focus has been placed upon developing biodegradable polymers which degrade over time.
In a previous study, van der Giessen et al has demonstrated that biodegradable polymers may induce marked infl ammatory reactions in the porcine coronary arteries, and that this may be attributable to the combination of the parent polymer compound, and biodegradation products 54 . Moreover, there are several factors which infl uence the velocity of degradation, either by accelerating or slowing it. Accordingly, It is has be stated that a balance between drug release kinetics, the rate of degradation of the polymer and the degradation products are essential for the success of bio-erodible stent systems in coronary vasculature 7 .
New families of biodegradable polymers have been tested recently in animal studies implemented by Lockwood and colleagues 55 which yield fewer acidic by-products than standard biodegradable polymers (PLGA, PLA) used in the currently available BioPol-DES, thus making it well-tolerated in vivo by providing a better degradation rate and biocompatibility profi le.
In an attempt to overcome the problems encountered with polymers or their degradation products, "polymer-free" drug eluting stents have evolved and have been proven to be safe in some clinical studies 13, 56 , and they were even associated with less late lumen loss compared to biodegradable-polymer and permanent-polymer stents in one study 13 . In a recent animal study, polymer-free biolimus A9 coated stents demonstrated more sustained intimal inhibition, improved healing and reduced infl ammation compared with the polymer coated sirolimus eluting Cypher ® stent 57 . One would expect that a DES without polymer will release the drug in a relatively short amount of time, resulting in relatively high systemic and tissue peak concentrations, however the superior pharmacokinetics and long half life of Biolimus A9 in the target tissues (Biolimus A9 was present in the coronary tissue until 180 days after stent implantation), made it a suitable drug for coating on non-polymer stents.
LIMITATIONS
To maximize the utilization of all available data, we included abstract presentations that have not been subjected to as much peer review and scrutiny as with full papers, and may not be as of high quality; however, we felt that this was necessary for two reasons. Including abstracts served as an additional tool to avoid any potential publication bias. The second reason is that the magnitude of treatment eff ect can be overestimated by analyzing only the published data 58 .
In our study only DST was used in the analysis, which may underestimate the true incidence of stent thrombosis among the studied stents. We preferred to use this end-point rather than overall stent thrombosis since not all the included studies reported stent thrombosis as defi nite, probable or possible according to the ARC defi nition 8 . In studies not using ARC defi nition, they stated in their defi nition of stent thrombosis that it was angiographically documented which matches defi nite stent thrombosis as defi ned by the ARC.
CONCLUSIONS
This meta-analysis, comparing diff erent biodegradable-polymer DES, showed that the risk of early DST and subsequently TLR were highest in the BioPol-BES at 30 days follow-up, whereas at 1 year there was signifi cantly less TLR in the BioPol-BES. We could observe a three times higher incidence of ST in BioPol-PES compared to BioPol-SES at 1 year. On comparing BioPol-DES and PermPol-DES in randomized clinical trials, there was no signifi cant diff erence in the risk of either TLR or stent thrombosis at 1 year.
These results point to the fact that BioPol-DES do not necessarily perform better than
PermPol-DES and that short-mid and long term results are to be carefully judged separately for newly emerging BioPol-DES before they can become a new standard.
